Positive News SentimentPositive NewsNASDAQ:INTS Intensity Therapeutics, Inc. Common stock (INTS) Stock Price, News & Analysis → BUY ALERT: Tiny tech play partners with US government (From Stansberry Research) (Ad) Free INTS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.71▼$4.8750-Day Range N/A52-Week Range N/AVolume8,704 shsAverage Volume22,761 shsMarket Capitalization$66.36 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrends Get Intensity Therapeutics, Inc. Common stock alerts: Email Address Intensity Therapeutics, Inc. Common stock MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside147.9% Upside$12.00 Price TargetShort InterestHealthy0.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.89Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.30 out of 5 starsMedical Sector774th out of 932 stocksBiological Products, Except Diagnostic Industry129th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingIntensity Therapeutics, Inc. Common stock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIntensity Therapeutics, Inc. Common stock has only been the subject of 1 research reports in the past 90 days.Read more about Intensity Therapeutics, Inc. Common stock's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.31% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics, Inc. Common stock has recently decreased by 14.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntensity Therapeutics, Inc. Common stock does not currently pay a dividend.Dividend GrowthIntensity Therapeutics, Inc. Common stock does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INTS. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Intensity Therapeutics, Inc. Common stock this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intensity Therapeutics, Inc. Common stock insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 3.74% of the stock of Intensity Therapeutics, Inc. Common stock is held by institutions.Read more about Intensity Therapeutics, Inc. Common stock's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioIntensity Therapeutics, Inc. Common stock has a P/B Ratio of 6.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Intensity Therapeutics, Inc. Common stock's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Intensity Therapeutics, Inc. Common stockIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Read More Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. INTS Stock News HeadlinesMay 15, 2024 | prnewswire.comIntensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of DirectorsMay 10, 2024 | prnewswire.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug CandidateMay 10, 2024 | finanznachrichten.deIntensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | msn.comINTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024May 9, 2024 | prnewswire.comIntensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 2, 2024 | finance.yahoo.comIntensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024March 18, 2024 | wsj.comOutlook Therapeutics Inc.March 15, 2024 | finanznachrichten.deIntensity Therapeutics Inc.: Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 14, 2024 | finance.yahoo.comIntensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 14, 2024 | prnewswire.comIntensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024February 21, 2024 | finance.yahoo.comIntensity Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 21, 2024 | prnewswire.comIntensity Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 8, 2024 | msn.comIntensity Therapeutics Unveils New Incentive Compensation PlanJanuary 18, 2024 | msn.comPerspective Therapeutics prices stock offering of $60.0M and $20.8M private placementJanuary 11, 2024 | seekingalpha.comINTS Intensity Therapeutics, Inc.January 3, 2024 | finanznachrichten.deIntensity Therapeutics Inc.: Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma ProgramJanuary 3, 2024 | finance.yahoo.comIntensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma ProgramDecember 29, 2023 | finance.yahoo.comIntensity Therapeutics (NASDAQ:INTS) Is In A Good Position To Deliver On Growth PlansDecember 27, 2023 | morningstar.comIntensity Therapeutics Inc INTSDecember 18, 2023 | msn.comCheckpoint stock plunges 50% on FDA rejection of skin cancer drugDecember 12, 2023 | finance.yahoo.comIntensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial OfficerDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate UpdateDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate UpdateDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceDecember 11, 2023 | finance.yahoo.comIntensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue SarcomaSee More Headlines Receive INTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intensity Therapeutics, Inc. Common stock and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/30/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INTS CUSIPN/A CIK1567264 Webwww.intensitytherapeutics.com Phone203 221 7381FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+147.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.39% Return on Assets-85.29% Debt Debt-to-Equity Ratio0.01 Current Ratio4.43 Quick Ratio4.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book6.82Miscellaneous Outstanding Shares13,710,000Free FloatN/AMarket Cap$66.36 million OptionableNot Optionable Beta4.03 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Lewis H. Bender M.A. (Age 63)M.B.A., M.S., Pres, CEO & Chairman Comp: $496.67kDr. Ian B. Walters M.B.A. (Age 54)M.D., VP & Chief Medical Officer Comp: $203.65kMr. James M. Ahlers (Age 58)Chief Financial Officer Mr. John Wesolowski CPA (Age 62)M.B.A., Principal Accounting Officer & Controller Mr. Brian Schwartz M.D.Exec. VP of Clinical Devel.Key CompetitorsBlack Diamond TherapeuticsNASDAQ:BDTXAdaptimmune TherapeuticsNASDAQ:ADAPCandel TherapeuticsNASDAQ:CADLMetagenomiNASDAQ:MGXInnate PharmaNASDAQ:IPHAView All CompetitorsInstitutional OwnershipMesirow Financial Investment Management Inc.Bought 44,177 shares on 4/26/2024Ownership: 0.322%Sapient Capital LLCBought 812,069 shares on 4/23/2024Ownership: 7.382%View All Institutional Transactions INTS Stock Analysis - Frequently Asked Questions Should I buy or sell Intensity Therapeutics, Inc. Common stock stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intensity Therapeutics, Inc. Common stock in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INTS shares. View INTS analyst ratings or view top-rated stocks. What is Intensity Therapeutics, Inc. Common stock's stock price target for 2024? 1 Wall Street analysts have issued 1-year price targets for Intensity Therapeutics, Inc. Common stock's shares. Their INTS share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 147.9% from the stock's current price. View analysts price targets for INTS or view top-rated stocks among Wall Street analysts. Are investors shorting Intensity Therapeutics, Inc. Common stock? Intensity Therapeutics, Inc. Common stock saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 21,300 shares, a decline of 14.1% from the April 30th total of 24,800 shares. Based on an average trading volume of 34,900 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.3% of the shares of the stock are sold short. View Intensity Therapeutics, Inc. Common stock's Short Interest. When is Intensity Therapeutics, Inc. Common stock's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our INTS earnings forecast. How were Intensity Therapeutics, Inc. Common stock's earnings last quarter? Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) announced its earnings results on Thursday, May, 9th. The company reported ($0.34) earnings per share (EPS) for the quarter. When did Intensity Therapeutics, Inc. Common stock IPO? Intensity Therapeutics, Inc. Common stock (INTS) raised $20 million in an initial public offering on Friday, June 30th 2023. The company issued 3,900,000 shares at a price of $5.00 per share. Who are Intensity Therapeutics, Inc. Common stock's major shareholders? Intensity Therapeutics, Inc. Common stock's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sapient Capital LLC (7.38%) and Mesirow Financial Investment Management Inc. (0.32%). This page (NASDAQ:INTS) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
